Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis: a case series

Abstract

The oral antifibrotic agent, pirfenidone (PFD), 5-methyl-l-phenyl-[1H]-pyridine, is used to treat idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. In trials, PFD reduces disease progression and decreases mortality. The most common side events of PFD are skin manifestations (25%), described as a photosensitivity or rash, but they are not well characterised ¹.

This article is protected by copyright. All rights reserved.

http://ift.tt/2x4IJKC